Clinical Trials Logo

Obstructive Sleep Apnea clinical trials

View clinical trials related to Obstructive Sleep Apnea.

Filter by:

NCT ID: NCT06312956 Recruiting - Clinical trials for Obstructive Sleep Apnea

Multidimensional Evaluation of Patients' Affected by Obstructive Apnea Syndrome (OSAS) Before and After Ventilotherapy

MULTI-OSAS
Start date: February 29, 2024
Phase:
Study type: Observational

This observational study aims to evaluate multiple dimensions of health in patients with Obstructive Sleep Apnea Syndrome (OSAS), before and after three weeks of ventilotherapy. Specifically, the study aims to identify pre- vs post-treatment differences in the following domains: - cognitive performance - blood expression of biomarkers related to neurodegeneration - psychosocial wellbeing Thus, patients will complete the following evaluations before (T0) and after (T1) ventilotherapy: - neuropsychological standard assessment - blood sampling - psychosocial self-reported questionnaires

NCT ID: NCT06311045 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

Start date: April 2024
Phase: N/A
Study type: Interventional

This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA.

NCT ID: NCT06306651 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

High Flow Nasal Cannula and Conventional Oxygen Therapy in the Postoperative Management of Patients With Mild to Moderate Obstructive Sleep Apnea

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

This study aims to compare the effectiveness of conventional oxygen therapy oxygen and high-flow nasal cannula therapy on oxygen saturation (SpO2), measuring number of SpO2 drop >4% of base line oxygen saturation (o2 desaturation index), length of the ICU stay, and the need of use supplemental continuous positive airway pressure (CPAP) support in any of the study groups in the postoperative ICU setting.

NCT ID: NCT06291870 Recruiting - Clinical trials for Obstructive Sleep Apnea

Predictors of Post-COVID Clinical and Cognitive Consequences

SCLC
Start date: January 19, 2023
Phase:
Study type: Observational [Patient Registry]

The CDC describes Post-acute sequalae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients. These sequelae may be present four or more weeks after SARS-COV-2 infection, including patients who had initial mild or asymptomatic acute infection. However, there is complete absence of data whether chronic sleep changes due to COVID-19 infection may influence these physical and mental health consequences. While fatigue is one of the common post-COVID conditions, there are no systematic examinations of sleep disturbances in COVID-19 survivors. This will be a pilot observational retrospective and prospective cohort study, to systematically assess if sleep disturbances and severity of sleep apnea comprise a modifiable facet of PASC as well as the short-term and longer-term effects of COVID-19 infection itself on sleep, cognitive function, exercise capacity and lung function.

NCT ID: NCT06286189 Recruiting - Clinical trials for Obstructive Sleep Apnea

Trazodone on OSA Endotypes

Start date: January 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Some OSA patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this protocol the investigators will test the effect of trazodone administered before sleep on OSA traits and OSA severity during sleep.

NCT ID: NCT06265792 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

Efficacy of Stellate Ganglion Block in Obstructive Sleep Apnea

OSA
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are: • Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

NCT ID: NCT06265129 Completed - Clinical trials for Obstructive Sleep Apnea

The Association Between Obstructive Sleep Apnea Severity and Red Blood Cells Indices

Start date: March 20, 2023
Phase:
Study type: Observational [Patient Registry]

Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of obstructive events (apnea and hypopnea) and intermittent hypoxia, which in turn contributes to the systemic inflammation that underlies this disease and its consequences (Ryan et al 2009, Gileles-Hillel et al 2014). This systemic inflammation leads to endothelial dysfunction, which contributes to the pathogenesis of cardiovascular complications in OSAS, in addition to the exposure to risk factors, such as male gender, older age, obesity, and lack of exercise (Lorenzi Filho et al 2010). Some red blood cells (RBC) and platelets indices have emerged as inflammatory biomarkers in various diseases (Tertemiz et al 2016) The severity of OSA is significantly associated with increase hematocrit, even after controlling for possible confounding variables. However, nocturnal hypoxemia in OSA does not usually lead to clinical polycythemia (Choi et al 2006). In patients referred with a clinical diagnosis of OSAS, RDW may be a marker for the severity of the condition. As RDW is usually included in a complete blood count, it could provide an inexpensive tool for triaging OSAS patients for polysomnography evaluation (Sökücü et al 2012). The hematological indices white blood cell count (WBC), neutrophil count, lymphocyte count, mean platelet volume (MPV), platelet distribution width (PDW), and red blood cell distribution width (RDW) have been proposed as alternative markers to those normally used clinically, e.g., interleukin-6 (IL6) and C-reactive protein, to evaluate the burden of inflammation in OSAS (Wu et al 2018)

NCT ID: NCT06264427 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Phenotypic and Genotypic Characterization of Patients With Dysmetabolism in Greenland

Start date: July 15, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to perform a detailed description of the feno- and genotype of people living with type 2 diabetes and severe obesity who are linked to care at Steno Diabetes Center Greenland. The main questions it aims to answer are: - Are monogenetic diabetes variants associated with the same risk of developing late diabetic complications as other types of diabetes? - Can genotyping and thereby personalized medicine be implemented in Greenland, and can personalized medicine lead to improved treatment? - What is the prevalence of sleep apnea among high-risk individuals in Greenland? - Is it possible to develop and implement a simple algorithm for the identification of sleep apnea in Greenland that can ensure treatment of severe sleep apnea? Participants will: - Answer WHO-5 and FOSQ-10 questionnaires regarding quality of life and functional outcomes of sleepiness - Perform VAGUS examinations for Cardiovasculare Autonomic Neuropathy - Clinical examination of height, weight, circumference of hip, waist and neck, Friedman tonsil and tongue score, nasal air flow, nasal septal deviation - Blood samples for full genome sequencing

NCT ID: NCT06264128 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

TPAP for Comfort in OSA

Start date: February 5, 2024
Phase: N/A
Study type: Interventional

TheraPAP is a prototype device (with full documented electrical and isolation safety) being developed by SleepRes for the treatment of obstructive sleep apnea (OSA) that can deliver either standard CPAP at a set pressure or what is called TPAP . TPAP is a pressure control algorithm that lowers the pressure from the set pressure at the beginning of inspiration and does not return the pressure to the full set level until about halfway through expiration. The present study, TheraPAP Comfort, aims at assessing whether TPAP improves patient comfort vs. CPAP during supine wakefulness.

NCT ID: NCT06263608 Recruiting - Atrial Fibrillation Clinical Trials

Structured Testing and Treatment for Obstructive Sleep Apnea in Patients With Atrial Fibrillation

STAROSA
Start date: February 23, 2024
Phase: N/A
Study type: Interventional

The main goal of this prospective pre-post implementation study is to investigate how a structured testing and treatment program for obstructive sleep apnea using the NOX T3s device and a Fitbit smartwatch with the FibriCheck algorithm impacts the proportion of atrial fibrillation (AF) in an AF population. Participants will wear the NOX T3s respiratory polygraphy device for one night at home. In case of a positive obstructive sleep apnea diagnosis, patients will be referred to the sleep clinic for a polysomnography examination. Patients positively diagnosed with polygraph will be monitored semi-continuously with the Fitbit smartwatch for three months. After the polysomnography examination, the positively diagnosed patients will be monitored semi-continuously for another three months after initiation of treatment (mostly continuous positive airway pressure (CPAP) treatment). Additionally, patients will be administered satisfaction and symptom burden questionnaires twice: right after the polysomnography examination and after the 3-month treatment.